Rational design of potent human transthyretin amyloid disease inhibitors

Nature Structural Biology

Volumn 7, Issue 4, 2000, Pages 312-321

  Klabunde, Thomas ^a,b   Petrassi, H Michael ^c   Oza, Vibha B ^c   Raman, Prakash ^c   Kelly, Jeffery W ^c   Sacchettini, James C ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 TRIFLUORMETHYLPHENYL ANTHRANILIC ACID; AMYLOID; DIBENZOFURAN 4,6 DICARBOXYLIC ACID; DICARBOXYLIC ACID DERIVATIVE; DICLOFENAC; DIFLUNISAL; FENOPROFEN; FLUFENAMIC ACID; FLURBIPROFEN; INDOMETACIN; M ANTHRANILIC ACID DERIVATIVE; MECLOFENAMIC ACID; MEFENAMIC ACID; N (3 TRIFLUOROMETHYLPHENYL)PHENOXAZINE 4,6 DICARBOXYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PREALBUMIN; PROTEIN INHIBITOR; RESVERATROL; UNCLASSIFIED DRUG;

AMYLOID NEUROPATHY; AMYLOIDOSIS; ARTICLE; CARDIOMYOPATHY; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG STRUCTURE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN STABILITY; PROTEIN STRUCTURE;

AMINO ACID SEQUENCE; AMYLOID NEUROPATHIES; ANTHRANILIC ACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZOFURANS; BINDING SITES; CARDIOMYOPATHIES; CRYSTALLOGRAPHY, X-RAY; DICARBOXYLIC ACIDS; DICLOFENAC; DRUG DESIGN; FLURBIPROFEN; HUMANS; HYDROGEN BONDING; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; OXAZINES; PREALBUMIN; PROTEIN STRUCTURE, QUATERNARY; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS;

EID: 0034127176     PISSN: 10728368     EISSN: None     Source Type: Journal    
DOI: 10.1038/74082     Document Type: Article

References (37)

1. Benson, M. D., Wallace, M. R. " Amyloidosis" In The Metabolic Basis of Inherited Disease (Scrirer, C. R., Beaudet. A. Z.. Sly, W. S., Velk, D. eds, New York: McGraw Hill. 2439-2460, 1989).
2. Colon, W. & Kelly, J.W. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 31, 8654-8660 (1992).
3. Kelly, J.W. Alternative conformations of amyloidogenic proteins govern their behavior. Curr. Opin. Struct. Biol. 6, 11-17 (1996).
4. Lai, Z.. Colon, W. & Kelly, J.W. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate which can self-assemble into amyloid. Biochemistry 35, 6470-6482 (1996).
5. Kelly, J.W. The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr. Opin. Struct. Biol. 8, 101-106 (1998).
6. McCutchen, S.L., Lai, Z., Miroy, G.J., Kelly, J.W. S Colon. W. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease. Biochemistry 34, 13527-36 (1995).
7. Jacobson, D.R. & Buxbaum, J.N. Genetic aspects of amyloidosis. Adv. Human Genetics 20, 69-123 (1991).
8. Sipe, J.D. Amyloidosis. Crit. Rev. Clin. Lab. Sci. 31, 325-354 (1994).
9. Benson, M.D., Uemichi, T. Transthyretin amyloidosis. Amyloid Int. J. Exp. Clin. Invest 3, 44-56 (1996).
10. nd ed. New York: Churchill Livingstone. 155-162, 1991).
11. Hodkinson, H.M., Pomerance, A. The clinical significance of senile cardiac amyloidosis: a prospective clinico-pathological study. O. J. Med. 46, 381-387 (1977).
12. Jacobson, D.R. et al. Variant-sequence transthyretin (isoleucin 122) in late-onset cardiac amyloidosis in black americans. N. Engl. J. Med. 336, 466-473 (1997).
13. Monaco, H.L, Rizzi, M. & Coda, A. Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein Science 268, 1039-1041 (1995).
14. Nilsson, S. F., Rack, L., Peterson, P. Studies of thyroid hormone binding proteins. J. Biol. Chem. 250, 8554-8563 (1975).
15. Blake, C.C., Geisow, M.J., Oatley, S.J., Rerat B. & Rerat, C. Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 Å. J. Mol. Biol. 121, 339-356 (1978).
16. Blake, C.C.F, Geisow, M.J., Swan, I.D., Rerat, C. & Rerat, B. Structure of human plasma prealbumin at 2.5 Å resolution. A preliminary report on the polypeptide chain conformation, quaternary structure and thyroxine binding. J. Mol. Biol. 88, 1-12 (1974).
17. Miroy, G.J. et al. Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc. Natl. Acad. Sci. USA 93, 15051-15056 (1996).
18. Wojtczak, A., Cody, V., Luft J.R. & Pangborn W. Structures of human transthyretin complexed with thyroxine at 2.0 Å Resolution and 3'-5'-Dinitro-N-acetyl-L-thyroxine at 2.2 Å Resolution. Acta Crystallogr. D 52, 758-765 (1996).
19. Peterson, S.A. et al. Inhibiting transthyretin conformational changes that lead to amyloid fibril formation. Proc. Natl. Acad. Sci. USA 95, 12956-12960 (1998).
20. Coelho, T. Familial amyloid polyneuropathy: new developments in genetics and treatment. Cuir. Opin. Neurol. 9, 355-359 (1996).
21. Munro, S.L. et al. Drug Competition for thyroxine binding to transthyretin (prealbumin): comparison with effects on thyroxine-binding globulin. J. Clin. Endorinol. Metab. 68, 1141-7 (1989).
22. Baures, P.W., Peterson, S.A., Kelly, J.W. Discovering transthyretin amyloid fibril inhibitors by limited screening. Bioorg. Med. Chem. 6, 1389-1401 (1998).
23. Baures, P.W., Oza, V.B., Peterson, S.A. & Kelly, J.W. Synthesis and evaluation of inhibitors of transthyretin amyloid formation based on the non-steroidal anti-inflammatory drug, flufenamic acid. Bioorg. Med. Chem. 7, 1339-1347 (1999).
24. Demrow, H.S., Slane, P.R., Folts, J.D. Administration of wine and grape juice inhibits in vivo platelet activity and thrombosis in stenosed canine coronary arteries. Circulation 91, 1182-88 (1995)
25. Bertelli A.A., et al. Antiplatelet activity of synthetic and natural resveratrol in red wine. Int. J. Tissue React. 17, 1-3 (1995).
26. MacCarrone M., Lorenzon T., Guerrieri P. & Agro A.F. Resveratrol prevents apoptosis in K562 cells by inhibiting lipoxygenase and cyclooxygenase activity, Eur. J. Biochem. 265, 27-34 (1999).
27. Cryer, B. & Feldman, M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J. Med. 104, 413-421 (1998).
28. Kurumbail R.G. et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 384, 644-648 (1996).
29. Oza, V.B., Petrassi, H.M., Purkey, H.E. & Kelly, J.W. Synthesis and evaluation of anthranilic acid-based transthyretin amyloid fibril inhibitors. Bioorg. Med. Chem. Lett 9, 1-6 (1999).
30. Horodniak, J.W. et al. Inhibition of prostaglandin synthetase and carrageenaninduced edema by analogs of flufenamic acid. Drugs Exptl. Clin. Res. 2, 35-45 (1977).
31. Petrassi, H. M., Klabunde, T., Sacchettini, J., Kelly, J. W. Structure-based design of N-phenyl phenoxazine transthyretin amyloid fibril inhibitors. J. Am. Chem. Soc. 122, in the press (2000).
32. Crook P.R., Willis, J.V., Kendall, M.J., Jack, D.B. & Fowler, P.D. The pharmacokinetics of diclofenac sodium in patients with active rheumatoid disease, fur. J. Clin. Pharmacol. 21, 331-334 (1982).
33. Diaz, H., Espina, J. R., Kelly, J. W. A dibenzofuran-based amino acid designed to nucleate antiparrallel β-sheet structure: evidence for intramolecular hydrogenbond formation. J. Am. Chem. Soc. Am 114, 8316-8318 (1992).
34. Otwinowski, J. & Minor, W. Processing of X-ray diffraction data in oscillation mode. Methods Enz. 276, 307-326 (1997).
35. Brunger. A.T. Crystallography & NMR System. Acta Crystallogr. D 54, 905-921 (1998).
36. Jones, T.A., Zou, J.-Y., Cowan, S.W. & Kjeldgaard, M. Improved method for building protein models in electron-density maps and the location of errors in these models. Acta Crystallogr. A 47,110-119 (1991).
37. Evans, S. V. SETOR: Hardware lighted three-dimensional solid model representations of macromolecules. J. Mol. Graphics 11,134-138 (1993).